TRDA רווח נקי למניה ב-12 החודשים האחרונים Entrada Therapeutics, Inc.
Collaboration with Vertex Pharmaceuticals is driving the growth of Entrada Therapeutics (TRDA), as evidenced by the trend in net income per share. The value of -3.84 represents the current level of the metric. Entrada Therapeutics (TRDA) leverages the Inertia platform to treat high-margin rare brain pathologies and attracts leading biochemists through a stock option system to accelerate the development of neuromuscular drugs.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20(EPS%20TTM)&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_TRDA_-_Entrada-Therapeutics_-_Net-earnings-per-share-EPS-TTM "TRDA Entrada Therapeutics, Inc: רווח למניה בשנים עשר החודשים האחרונים בטווח 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
Entrada Therapeutics, Inc - פילוחים אנליטיים ומדדי מפתח (TRDA)
Entrada Therapeutics (TRDA) utilizes its innovative EEV platform for cellular drug delivery, creating unique therapeutic potential within the incurable disease segment. This 12-month net income per share chart digitizes the effectiveness of this strategy, dividing total net income by the number of outstanding shares to assess the real return on each equity stake, excluding dilution from new issuances.
